The AI technology firm and pharma services company are joining to help one of the country’s leading pharmaceutical firms develop a promising drug candidate.
An expert from the IRB and study solutions firm explains how advanced analytics can lead to several benefits, including shortened trial startup timelines.
This month’s news on appointments, expansions, acquisitions and other events includes Nanoform, Elligo Health Research, Curavit, and other organizations.
A representative from the school explains how tools like artificial intelligence and natural language processing can help elevate personalized medicine.
A study by Charles River finds patients believe the overall quality of healthcare would increase if stakeholders across the life sciences collaborated more.
A leader from Firma Clinical Research advises that while using RWD can be daunting, putting the data to use can lead to a number of notable advantages.
Stakeholders in the Rare Disease Cures Accelerator-Data and Analytics Platform initiative are partnering in hopes of bringing treatments to patients faster.
This month’s roundup of new technology, equipment, and industry partnerships includes news from IBM, IQVIA, Mediata, Labcorp, and other notable companies.
The pharma tech firm has forged a four-year partnership with the foundation to develop antivirals for COVID-19 and other viruses with pandemic potential.
The US medical research agency plans to offer funding over five years through a newly launched consortium, expected to include 30 sites across the country.
The digital therapeutics firm's Neuroglee Connect remote care platform and virtual clinic is for patients with mild cognitive impairment, including Alzheimer’s.
This month’s news on new hires, board launches, acquisitions, and other important news includes items on Pfizer, Javara, Clinical Ink, and other companies.
According to patient-matching specialist TrialJectory, 90% of cancer patients know the vitality of genetic testing but more than half are not being tested.
The #BlackDataMatters movement aims to improve outcomes for Black women living with breast cancer by increasing their presence in vital clinical research.
Merck (known as MSD outside the US and Canada) will partner with the data insights firm on solutions that progress real-world research and innovations.
The CRO has launched an initiative that offers help navigating regulatory issues for ultra-rare disease patient advocacy groups that demonstrate a need.
The drug discovery company reportedly used AI-powered drug discovery to come up with a promising preclinical candidate for treatment of the kidney ailment.
The two firms will work together on solutions to connect de-identified, first-party data to real-world data to help advance precision medicine development.
The digital pathology firm and image-analysis software developer will partner on artificial intelligence based solutions to improve trial decision making.
The Heart of Athletes study, using Deloitte’s ConvergeHealth MyPath for Clinical platform, aims to examine heart inflammation in athletes with the virus.
The pharma firm is working with five US colleges and universities onto create programming designed to boost recruitment of Black talent in the industry
The University of Illinois at Chicago has been given $6m from the US Department of Defense to develop a potential treatment for severe cases of COVID-19.
The Psychae Institute, established by a global team of scientists, will conduct pre-clinical and clinical research around psychedelic medicine development.
The two companies are collaborating to research, develop and launch new small-molecule drug candidates aimed at treating obesity and related comorbidities.
A new UK eLearning program is targeted at healthcare and academic professionals to support their learning on advanced therapy medicinal products (ATMPs).
A leader from the artificial intelligence solutions firm discusses how advanced analytical tools can help researchers make the most of mountains of data.
The process management solutions firm says drug companies could use contract data to get a better handle on predicting demand and adjusting product output.
The oncology-centered analytics firm will work with the DC-area healthcare provider to delve into discovery and development of novel cancer treatments.
The past several days have seen a relatively large number of industry acqusitions, with Lilly, Phillip Morris, WCG, CTI and others making notable buys.
The two companies will work together to come up with solutions that use machine learning and artificial intelligence to help accelerate innovation in R&D.
According to a leader from CRO Quanticate, the research industry’s increased use of real-world data is leading to a broad range of benefits in trial work.
US President Joe Biden singled out the pharmaceutical industry in his recently issued Executive Order on Promoting Competition in the American Economy.
During the Rare/Orphan Diseases, Special Patient Population webinar, a group of industry experts discussed challenges and opportunities faced in the field.
The organization, focused on building awareness and finding therapies for the rare disease, is boosting its annual research funding to more than $2.7m USD.
The project will use the artificial intelligence specialist’s cell-centered models and deconvolutions to gain insights for each individual asthma endotype.
This month’s roundup of new equipment, materials, tech partnerships and other news includes items from Ajinomoto, Evonik, Quanticate, Pharmasol, and more.
An academic researcher and and company expert discuss on how evolving cryogenic electron microscopy has led to high resolutions and accelerated results.
Medable will collaborate with Aural Analytics in an initiative funded by the NIH’s seven-year Beau Biden Cancer Moonshot research and development program.
In recent years, it has become clear that RNA molecules are an emerging as a class of therapeutics of relevance to multiple diseases, most recently including COVID-19 vaccines.
Decentralized trials and remote monitoring, long discussed, but never really taking off until COVID-19 disrupted studies last year, will be under the spotlight at the DIA 2021 Annual Meeting at the end of this month.
Whether working in the pharmaceutical industry or in academia or government, the skills required to achieve, maintain and grow a career are vastly different today than they were 30 years ago. A session at DIA 2021 will put the spotlight on the skills...
